Founded in 2014, XtalPi founders recognized a common hurdle in drug development having to do with solid polymorphism, which they successfully tackled with quantum physics predictions. Since then, XtalPi has maintained its focus on identifying and then attacking traditional bottlenecks in biopharmaceutical R&D through innovative technologies. Through considerable capital investments in automation and personnel, XtalPi now has four locations worldwide and employs approximately 1000 employees. XtalPi has engaged in collaboration research with nearly all top-20 pharmaceutical companies in the world. Its ID4 platform combines physics-based simulations with experimental validation and refinement, automation for rapid chemical synthesis, and machine learning to continuously improve prediction accuracy and process efficiency.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Tools/Drug Development Support Tech
Lead Product in Development:
Autonomous chemical synthesis workstations. Integrated AI-driven drug discovery platform. Three products in early pipeline for licensing.
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
